Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,121 across all filing types
Latest filing 2015-05-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Appendix 3B 9 pages 377.5KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3B' and is an announcement related to the issuance of new securities, specifically fully paid ordinary shares and employee options. It includes detailed information about the class, number, terms, issue price, purpose of the issue, and quotation of securities on the ASX. The document is a formal notification to the Australian Securities Exchange (ASX) about a capital raising event through the exercise of unlisted options and the subsequent quotation of these securities. There are no financial statements, management discussion, or audit information present. The content aligns with announcements about new share issues or capital changes rather than a full financial report or other categories. Therefore, the document fits the category of 'Share Issue/Capital Change' (SHA). The document length (12,697 characters) is sufficient to be a full announcement rather than a brief notice or report publication announcement.
2015-05-05 English
US Oxycodone franchise restructure and Doryx re-launch 2 pages 246.0KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 4 May 2015 from Mayne Pharma Group Limited. It discusses operational updates such as taking control of the US Oxycodone product franchise from Mylan, the re-launch of the Doryx product with a new sales team, and strategic business developments. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is relatively short (4278 characters) and serves as a business update rather than a formal financial report or regulatory filing. It does not announce voting results, changes in board or management, or capital structure changes. It is not a call transcript, earnings release, or merger announcement. The content fits best as a Capital/Financing Update (CAP) because it relates to control over product franchises and operational restructuring impacting earnings, which are typical subjects of capital and financing updates.
2015-05-03 English
Appendix 3B 9 pages 384.5KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically additional fully paid ordinary shares and employee options. It includes details such as the number of securities issued, issue price, terms of securities, and compliance with ASX listing rules. The document is a formal notification to the Australian Securities Exchange (ASX) about the issuance and quotation of additional securities. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of a capital/financing event related to share issuance. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (13,702 characters) and content confirm it is a full announcement rather than a brief notice or a report publication announcement.
2015-04-13 English
Appendix 3B 9 pages 469.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an official form used for announcing new issues of securities, application for quotation of additional securities, and related agreements. It contains detailed information about the class, number, terms, issue price, purpose of securities issued, and compliance with ASX rules. The document is a regulatory announcement related to capital raising and securities issuance, specifically the issuance of fully paid ordinary shares and employee options. It is not a financial report, earnings release, or management discussion, but rather a formal notification to the stock exchange about capital changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is a substantive announcement, not a brief notice or report publication announcement.
2015-03-26 English
Appendix 3B 9 pages 469.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B' and is an announcement related to the issue of new securities, specifically additional fully paid ordinary shares and employee options. It includes details such as the number of securities issued, issue price, terms, and application for quotation on the ASX (Australian Securities Exchange). The document is a formal notification to the exchange about a capital raising event through the exercise of options and the subsequent listing of these securities. It does not contain financial statements, management discussion, or detailed financial results. It is not a report but an announcement of a capital/financing activity. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the securities issued, consistent with a capital/financing update rather than a brief notice or regulatory filing.
2015-03-18 English
Change of Director's Interest Notices (x3) 6 pages 1.0MB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by company directors, including number of shares held before and after the change, nature of the interest, and consideration paid. The document is a formal notification of personal share transactions by company directors. It does not contain financial performance data, management discussion, or other report content. This matches the definition of Director's Dealing filings, which report personal share transactions by company directors and executives (insider trades). The document length is over 10,000 characters and contains multiple such notices for different directors, confirming it is not a brief announcement but a detailed insider trading report.
2015-03-16 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.